• Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion
    Motley Fool

    Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

    Blueprint Medicines (NASDAQ: BPMC) announced Tuesday that global biopharma giant Roche Holdings (OTC: RHHBY) is paying up to $1.7 billion in upfront cash and potential milestones, plus royalties, to obtain commercial rights to market pralsetinib outside the U.

  • Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
    Zacks

    Blueprint Medicines, Roche to Develop Pralsetinib for Cancer

    Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.

  • Here's Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine
    Motley Fool

    Here's Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine

    Vaccine development is not an all-or-nothing endeavor. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful.

  • Roche to pay Blueprint up to $1.7 billion in cancer drug deal
    Reuters

    Roche to pay Blueprint up to $1.7 billion in cancer drug deal

    Swiss drugmaker Roche <ROG.S> on Tuesday struck a deal worth up to $1.7 billion (£1.35 billion) with Blueprint Medicines <BPMC.O> to develop and commercialise a new treatment for people with so-called RET-altered cancers whose mutations can drive tumour growth. Roche, which has had a pact to develop drugs with Blueprint Medicines since 2016, will pay $675 million in cash and make a $100 million equity investment to get rights to pralsetinib, in late-stage development for people with RET-altered non-small cell lung cancer as well as other cancers. U.S.-based Blueprint could also get up to $927 million in milestones, plus royalties on sales outside the United States, Basel-based Roche said in a statement.

  • Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?
    Investor's Business Daily

    Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

    Blueprint Medicines stock popped Tuesday on a $775 million deal with pharma giant Roche to sell a cancer treatment, pralsetinib. The drug targets abnormalities in the RET gene.

  • Why Bristol-Myers Squibb (BMY) Stock is a Compelling Investment Case
    Insider Monkey

    Why Bristol-Myers Squibb (BMY) Stock is a Compelling Investment Case

    On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

  • MarketWatch

    Blueprint Medicines shares gain on deal with Roche

    Shares of Blueprint Medicines Corp. gained 8.3% in premarket trading on Tuesday, the day after the company announced a deal with Roche Holding AG to develop and commercialize pralsetinib, an investigational cancer drug. Roche will pay $775 million upfront in cash and equity to gain exclusive worldwide licensing rights to the treatment excluding China and the U.S. The deal also includes up to $927 million in milestone payments. Blueprint's stock is down 4.3% year-to-date. The S&P 500 has declined 2.3% since the start of the year.

  • Roche gene testing key to $1.7 billion deal for Blueprint cancer drug
    Reuters

    Roche gene testing key to $1.7 billion deal for Blueprint cancer drug

    Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines, it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments. The Swiss drugmaker will pay $675 million in cash and make a $100 million equity investment in Blueprint for rights to pralsetinib, which could gain U.S. approval against so-called RET-altered non-small cell lung cancer in November. U.S. company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States, Roche said in a statement.

  • Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
    PR Newswire

    Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

    Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize pralsetinib, an investigational once-daily oral precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), other thyroid cancers and other solid tumors. Under the collaboration, Blueprint Medicines and Genentech will co-commercialize pralsetinib in the U.S. and Roche will obtain exclusive commercialization rights for pralsetinib outside of the U.S., excluding Greater China. The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor as part of this collaboration.

  • Did Hedge Funds Make The Right Call On Blueprint Medicines Corporation (BPMC) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Blueprint Medicines Corporation (BPMC) ?

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • GuruFocus.com

    Roche Forecasted to Be Top Drug Seller in 2026

    AstraZeneca and Bristol-Myers Squibb's revenues expected to grow the fastest Continue reading...

  • Did Hedge Funds Make The Right Call On Seattle Genetics, Inc. (SGEN) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Seattle Genetics, Inc. (SGEN) ?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Did Hedge Funds Make The Right Call On XACT Sciences Corporation (EXAS) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On XACT Sciences Corporation (EXAS) ?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • Could Buying Inovio Pharmaceuticals Stock Make You Rich?
    Motley Fool

    Could Buying Inovio Pharmaceuticals Stock Make You Rich?

    Over the five-year period leading up to 2020, Inovio Pharmaceuticals (NASDAQ: INO) delivered a positive return in just one year: In 2016, Inovio gained a little over 3%. The company has emerged as one of a handful of small drugmakers with promising COVID-19 vaccine candidates. Could buying Inovio stock now make you rich over the next several years?

  • Notable Insider Buys: Acceleron, Continental And Syneos Health
    Benzinga

    Notable Insider Buys: Acceleron, Continental And Syneos Health

    * Insider buying can be an encouraging signal for potential investors. * The executive chair of a petroleum production company returned to the buy window last week. * Notable insider purchases were also seen at two biopharmaceutical companiesConventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and economic uncertainty. Here are some of the most noteworthy insider purchases reported in the past week.Continental Resources Continental Resources, Inc. (NYSE: CLR) saw its founder and executive chair, Harold Hamm, return and purchase more than 1.52 additional shares last week. At per-share prices between $16.23 and $18.10, that totaled nearly $26.74 million. His stake is up to more than 12.29 million shares. The total float is about 69.8 million shares.Hamm has been buying shares for almost a month, pursuant to a Rule 10b5-1 plan. Continental Resources stock pulled back more than 12% last week and was last seen at $16.03 a share. That is below Hamm's most recent purchase price range. The share price still is up nearly 8% since the year-to-date low back in early March.Acceleron Acceleron Pharma Inc (NASDAQ: XLRN) saw 10% owner and partner Celgene recently take advantage of a secondary offering to acquire more than 108,000 shares for $92.50 apiece. That totaled just shy of $10 million. Note that Celgene is a subsidiary of Bristol-Myers Squibb Co. (NYSE: BMY).Cambridge Massachusetts-based Acceleron recently posted positive heart drug study results. Its stock closed down marginally last week at $99.99 a share, above Celgene's purchase price. The share price is more than 88% higher since the beginning of the year but has a consensus target price of $123.80.See Also: Insider Sells Marvell Technology Group's SharesSyneos Health A director purchased almost 8,700 Syneos Health Inc (NASDAQ: SYNH) shares early last week. The share price was $59.11, and the total for the transaction came to more than $513,700. This also was pursuant to a 10b5-1 trading plan, and that director's stake almost doubled.Its second-quarter earnings report is due August 6. Syneos Health shares ended last week about 2% lower to $56.38. That is below the above purchase price. While the share price is about 33% higher since its year-to-date low in March, it is still well below its consensus price target of $64.67.Furthermore, note that some amount of insider buying at Bloomin' Brands Inc (NASDAQ: BLMN), Cooper Companies Inc (NYSE: COO) and Herman Miller, Inc. (NASDAQ: MLHR) was reported last week as well.See more from Benzinga * Notable Insider Buys: Novartis, T-Mobile And More * Notable Insider Buys: Continental Resources, Fox, Groupon And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Coronavirus Vaccine Race: Moderna or Inovio?
    Motley Fool

    Coronavirus Vaccine Race: Moderna or Inovio?

    Multiple drugmakers are scrambling to develop COVID-19 vaccine candidates. In terms of clinical progress, Moderna (NASDAQ: MRNA) appears to be neck-and-neck for the lead with a partnership between AstraZeneca and the University of Oxford. The U.S. biotech hopes to begin a pivotal late-stage study of its COVID-19 vaccine candidate mRNA-1273 later this month.

  • INO Stock Could Receive Operation Warp Speed Funding Soon
    InvestorPlace

    INO Stock Could Receive Operation Warp Speed Funding Soon

    Will Inovio (NASDAQ:INO) and INO stock explode, or is its run over? Creating vaccines requires massive resources. Thus, questions regarding the ability of smaller biotech companies to compete with their better-heeled and more experienced adversaries have persisted. Yet, the potential return on smaller biotech companies was and perhaps remains too tempting.Source: Ascannio / Shutterstock.com Reports that government scientists are having trouble running trials with Moderna (NASDAQ:MRNA) don't bode well for smaller biotech companies pursuing a vaccine. That much larger drug makers like Johnson & Johnson (NYSE:JNJ) have not received such complaints is telling. This points to the sophistication and advanced nature of the large drug makers' Covid-19 programs. Perhaps they are simply better versed in cooperating with the government. Nevertheless, investors should recognize the risk these smaller biotech stocks represent. Inovio may yet receive government funding and explode.InvestorPlace - Stock Market News, Stock Advice & Trading Tips A Reversal of Fortune at Inovio?Barron's reports a reversal of analyst sentiment regarding Inovio within the past month. One month ago the tally was five "buys," three "holds", and no "sells." Consensus was that the stock was overweight at that time. However, the current tally is two "buys," five "holds," and one "sell" with the consensus being to hold it. * The 7 Best Stocks to Invest in Right Now Investors should bear this change of sentiment in mind given recent news concerning Novavax (NASDAQ:NVAX) and Regeneron (NASDAQ:REGN). The federal government signed a $450 million contract with Regeneron to purchase as many as 1.3 million does of its antibody cocktail. Novavax announced that it received $1.6 billion to test its Covid-19 vaccine. Novavax does not have any commercially marketed products and yet it is receiving $1.6 billion in funding. Markets should interpret this as one of two things: either the government is hedging a massive bet, or it knows more about Novavax's vaccine than has been released. Given that Novavax shares popped 29% following the funding news, markets are betting on the latter. Inovio Seeking Government CooperationInovio's ability to leverage government relationships in the fight against the pandemic is crucial. It seeks to do what Novavax and Regeron have recently achieved. Former U.S. military vaccine and pandemic expert Dr. Mammen Mammen joined Inovio on June 25 to lead clinical development of the vaccine. Two days prior, Inovo received $71 million in funding to scale up manufacturing of its vaccine delivery device. Inovio's CELLECTRA 3PSP proprietary delivery device delivers INO-4800 directly into the skin. Investors are keenly scrutinizing these developments and their potential.Markets also want to know when peer review news will be released relating to INO-4800. This will be very important on the heels of the news released on June 30. Inovio's June 30 press release regarding phase 1 data for their INO-4800 vaccine didn't spike the price. Market reactions indicated some skepticism regarding Inovio's claims about INO-4800. Thus, investors will await peer review for the drug, which will likely serve to confirm or discredit the company-issued June 30 statement. Inovio also stated that it will begin a 2-stage trial in Korea. Inovio announced it added Gene Kim to its management team. He has a long history of leading Korean biotechs and previously helped list an IPO. INO Shares Might Rise to Warp SpeedThe federal government's largest expenditure in Operation Warp Speed thus far has been its bet on Novavax. The government's $1.6 billion bet is a clear indication that unproven biotech companies are a pillar of its Covid-19 strategy. Signs certainly point to a possible Operation Warp Speed funding announcement of Inovio in the coming weeks. Despite the market's tepid reception of Inovio's June news, there are signs of something big coming. The company is scrambling and aligning a coherent strategy in this volatile environment. Investors can also assume that a government funding deal is being discussed. Is INO Stock a Buy?INO stock is absolutely a hold and given all of the signs, one to consider as a Covid-19 play. Inovio has huge upside. The more I read about this stock the more I feel like investors are going to only regret not buying it. However, this is all speculation. Inovio could certainly strike out in regards to INO-4800. The company, however, has many other products in its pipeline and I can't help but feel like it's headed somewhere positive. As of writing, Alex Sirois does not own any of the aforementioned stocks. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post INO Stock Could Receive Operation Warp Speed Funding Soon appeared first on InvestorPlace.

  • 3 Reasons to Invest in, Not Trade iBio
    InvestorPlace

    3 Reasons to Invest in, Not Trade iBio

    Stuck in a "soft" quarantine, I turned to what most people did during the hard quarantine - watch the film Contagion. It's been quite a while since I last saw the terrifying depiction of a devastating pandemic. After giving it another run through, I'm struck at how ominously accurate the movie is regarding the novel coronavirus. And this brings me to iBio (NYSEAMERICAN:IBIO) and specifically, IBIO stock.Source: Shutterstock Over the last few months that I covered this biotechnology firm, I described its equity as a speculative opportunity to advantage with "dumb" money. In other words, as a pure gamble, you could do a lot worse. Should the organization live up to its claim of mass-production of a coronavirus vaccine, IBIO stock could veritably skyrocket.But as shares have steadily ticked higher since early April and as demand for a vaccine consistently rises, I'm willing to sharpen my prognostication for iBio. Rather than it being a dumb money move, it's a rational one.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDon't get me wrong - IBIO stock is still ultra-risky. However, what has given me more confidence in the underlying company is that a return to normalcy may be impossible without a biological solution to this crisis.In carefully watching Contagion, I realized what made this narrative so compelling from a filmmaking perspective is plot organization. Starting with the initial strike, the protagonists work through the fictional MEV-1 virus' second wave, which then culminates in a vaccine and its unwieldy distribution. * The 7 Best Stocks to Invest in Right Now Each segment in the film features its own conflict. What intrigued me about Contagion's final act was that the mere production of a vaccine wasn't enough. This brings me to my first of three bullish factors for iBio. Scale Is the Distinguisher for IBIO StockAs the New York Times spelled out a few months ago, several entities are developing a novel coronavirus vaccine. Contrary to some people's opinions, this development process is long, arduous and expensive. It's not as easy as injecting disinfectants.Therefore, you're looking at a two-front battle. First, a pharmaceutical company must forward a truly viable and effective vaccine. Second, it's got to bring that vaccine to scale so that the entire nation can benefit. Both challenges will be difficult to overcome.But as I pointed out in early June, scale is what distinguishes IBIO stock from the competition. I wrote:The driving force behind the company is a proprietary technology called the FastPharming Manufacturing System. Using a relative to the tobacco plant as a "bioreactor," iBio can theoretically take a vaccine and scale it up to necessary commercial volume. According to iBio co-chairman and CEO Tom Isett, the firm can "make about 500 million doses of high-quality product annually."Granted, the company must live up to its claims. Otherwise, it can go downhill quickly for IBIO stock. Nevertheless, if it can achieve this scale, the U.S. government's ambitious target to get a vaccine within a 12- to 18-month window is much more credible. Multiple Paths to SuccessAnother previously not well known pharmaceutical company in the coronavirus vaccine race is Inovio Pharmaceuticals (NASDAQ:INO). Despite question marks over its candidate's viability, INO shares are still performing outstandingly. In part, this may be because there are multiple paths to success.According to Dr. James Samuel, a regents' professor and the head of the Department of Microbial Pathogenesis and Immunology at the Texas A&M University College of Medicine, initial coronavirus vaccines may be helpful for healthy individuals. However, Dr. Samuel cautioned that other vaccines may need to be developed for medically vulnerable individuals.As Dr. Samuel put it, "The challenge is a lot more complicated than a single vaccine… The scale of the problem alone is unprecedented. This will not be a horse race with a single winner."Therefore, just because a company beats everyone else to an effective vaccine doesn't spell disaster for others. First, scaling up that vaccine is a challenge, but one that would better suit iBio. Second, multiple vaccines may be necessary to fully address the Covid-19 pandemic.So, IBIO stock may have a safety margin that some investors may not be aware of. Economic Demand Is SurgingWhoever forwards genuine solutions, investors of that organization will find themselves loving life (assuming they don't get Covid-19 and die). But the financial implications of a vaccine don't just end on Wall Street. Indeed, the domestic and perhaps the international economy is dependent on it.For the most part, Americans have graciously adopted previously foreign practices, such as wearing masks and practicing social distancing. But skyrocketing new daily coronavirus cases, along with an uptick in Covid-19-related deaths have cast a shadow on these measures' efficacy.If only from the power of perception, the U.S. desperately needs a vaccine. It's much easier to convince businesses to reopen and people to spend if we have a substantive, meaningful solution.This also means that there's extra leeway in terms of the vaccine development process. Stated differently, a less-than-desirable result may not spell immediate red ink for pharmaceutical players. And that adds another measure of confidence toward IBIO stock.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 3 Reasons to Invest in, Not Trade iBio appeared first on InvestorPlace.

  • Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer
    Benzinga

    Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer

    Inovio Pharmaceuticals Inc (NASDAQ: INO) could be embroiled in a prolonged legal battle with its Blue Bell, Pennsylvania-headquartered subcontractor VGXI, Inc, after the subcontractor sued the pharma company. The Inovio Lawsuit: VGXI filed a lawsuit this week in the Montgomery County Court of Common Pleas, with the plaintiff accusing Inovio of breach of contract, unfair competition, misappropriation of trade secrets and unjust enrichment, the Philadelphia Business Journal reported.Inovio initiated legal proceedings against VGXI, a subsidiary of South Korea's GeneOne Life Sciences, in early June, accusing it of not transferring technical know-how to manufacture doses of INO-4800, Inovio's DNA vaccine candidate against SARS-CoV-2.Inovio's contention was that VGXI did not possess the wherewithal to scale up manufacturing, which is essential for getting regulatory clearance.In late June, the Montgomery County Court denied Inovio's request for an injunction against VGXI."Inovio got greedy. It saw the opportunity to reap vast riches and keep its stock price soaring if it could win the race to a COVID-19 vaccine, but Inovio did not want to pay VGXI for the manufacturing," VGXI reportedly said in the lawsuit.Inovio chose to unfairly take possession of VGXI's proprietary technology and manufacturing processes and pass on to as many as 10 other manufacturers around the world, including in China and India, the lawsuit alleges. What's Next For Inovio: The lawsuit from VGXI will not impact Inovio's coronavirus vaccine development, an Inovio spokesman told Benzinga in an email Friday. "If we have an effective vaccine, manufacturing will not be an issue," he said, adding that the Phase 2/3 trail for INO-4800 is on track to begin this summer.Inovio reported June 30 with interim results from a Phase 1 study of INO-4800, which showed that 94% of Phase 1 trial participants demonstrated immune responses at week six after two doses of INO-4800.The company also announced it has been selected to take part in a non-human primate challenge study under the federal government's Operation Warp Speed..Inovio shares were down 0.67% at $23.12 at last check.Related Links:Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine See more from Benzinga * The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus * Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start
    Bloomberg

    Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start

    (Bloomberg) -- Seventeen months into her stint at the top of Agios Pharmaceuticals Inc., Jackie Fouse knows things could have gone better for investors.Shares of the drug developer have languished since Fouse took the helm in February 2019, even as the industry climbed to all-time highs, in part due to the company’s financing and competitive concerns. Now she’s turning her focus to longer-term growth and advancing non-cancer therapies in a bid to win back investors’ trust.“If somebody was going to measure my performance, at least only on the basis of the stock price, I have not done a very good job for the last year and a half,” Fouse joked in a telephone interview. “We’ve got to work very hard to show that our drug is differentiated from the competition,” she said in reference to mitapivat, an experimental therapy for disorders like sickle cell anemia that analysts say could one day top $1 billion in sales.One of investors’ biggest complaints has been how quickly Agios burns through cash. The company has spent more than $1 billion on research and development since 2017 compared to revenue of about $255 million over that stretch, data compiled by Bloomberg show.“I don’t think the criticism around the cash burn has completely gone away,” Fouse said. “We’ve been chipping away at that.”Agios has two products on the market -- one wholly owned and one partnered with Bristol Myers Squibb Co.’s Celgene -- though Wall Street has been focused on mitapivat. The experimental medicine “may end up being a multi-billion dollar drug,” according to Fouse. However, efforts in sickle cell face competition from Global Blood Therapeutics Inc.’s Oxbryta and experimental therapies from Bluebird Bio Inc. and partners Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG.“While Agios aims to initiate pivotal trials in thalassemia and sickle cell anemia in 2021, mitapivat’s safety profile in SCA could become a critical factor in a future competition with Oxbryta, which has demonstrated compelling safety data,” Oppenheimer analyst Mark Breidenbach wrote in a June 14 note.For Wall Street analysts, Agios’s ability to nab Fouse was a steal. Amid speculation she would take the top job at Gilead Sciences Inc. -- since filled by Daniel O’Day -- Fouse said the allure of a smaller company was attractive. She wouldn’t say whether Gilead had approached her to become CEO, instead saying she was “approached about a lot of jobs” after she left Celgene in 2017.Shares of Cambridge, Massachusetts-based Agios are down 1% since Fouse took over in February of last year. That compares to a 27% rally for the closely watched Nasdaq Biotechnology Index and places it 127th among the index’s 206 companies.The next catalyst for Agios shares is likely to come later this year with additional results from the early-stage trial of mitapivat in sickle cell. Data for a pair of studies in pyruvate kinase deficiency are also due between year-end and the middle of 2021.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • GlobeNewswire

    MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

    Rockville, MD, July 09, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Here's Why MacroGenics Jumped 156.6% in the First Half of 2020
    Motley Fool

    Here's Why MacroGenics Jumped 156.6% in the First Half of 2020

    Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.

  • Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the Upgrade
    Zacks

    Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the Upgrade

    Bristol Myers (BMY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.